| CAS: | 4682-36-4 | |||
| 分子式: | C18H23NO.C6H8O7 | |||
| 分子量: | 461.51 | |||
| 中文名称: |
| |||
| 英文名称: |
|
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| O797069 | MACKLIN | 奥芬那君 柠檬酸盐 | 10mM in DMSO | 160元/1ml; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
储存:-20°C, 密封, 干燥 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PHR1777 | Supelco | Orphenadrine Citrate | Pharmaceutical Secondary Standard; Certified Reference Material | 1568.52元/1 G; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. 应用 These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements. 生化/生理作用 毒蕈碱型受体拮抗剂;H1 组胺受体拮抗剂;肌肉松弛剂。据报道,奥芬那君还可抑制去甲肾上素转运蛋白并且阻塞 NMDA 受体离子通道。 分析说明 These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. 其他说明 This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. 附注 To see an example of a Certificate of Analysis for this material enter LRAA8433 in the Documents slot below. This is an example certificate only and may not be the lot that you receive. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Y0000101 | Orphenadrine Citrate | European Pharmacopoeia (EP) Reference Standard | 1277.32元/ ; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. 生化/生理作用 毒蕈碱型受体拮抗剂;H1 组胺受体拮抗剂;肌肉松弛剂。据报道,奥芬那君还可抑制去甲肾上素转运蛋白并且阻塞 NMDA 受体离子通道。 包装 Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 注意 Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| O4630 | Supelco | Orphenadrine citrate salt | analytical standard | 667.82元/5 G; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 应用 Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support. 包装 5 g in poly bottle 生化/生理作用 毒蕈碱型受体拮抗剂;H1 组胺受体拮抗剂;肌肉松弛剂。据报道,奥芬那君还可抑制去甲肾上素转运蛋白并且阻塞 NMDA 受体离子通道。 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1479009 | USP | Orphenadrine citrate salt | United States Pharmacopeia (USP) Reference Standard | 3231.47元/200 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. 生化/生理作用 毒蕈碱型受体拮抗剂;H1 组胺受体拮抗剂;肌肉松弛剂。据报道,奥芬那君还可抑制去甲肾上素转运蛋白并且阻塞 NMDA 受体离子通道。 分析说明 These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. 其他说明 USP issued SDS can be found here. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HY-B0369A | MCE | Orphenadrine citrate,4682-36-4,枸酸芬那君_MCE(MedChemExpress) | 220元/10 mM * 1 mL in DMSO; 200元/50 mg; 320元/100 mg; 760元/500 mg; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。 Orphenadrine citrateMCE 国际站:Orphenadrine citrate 品牌:MedChemExpress (MCE) 货号:HY-B0369A CAS 号:4682-36-4 生物活性:枸橼酸奥芬那君是一种口服有效的非竞争性NMDA受体拮抗剂(可穿过血脑屏障),其Ki值为6.0 μM。枸橼酸奥芬那君可缓解肌肉拉伤、扭伤或其他损伤引起的僵硬、疼痛和不适。枸橼酸奥芬那君也用于缓解帕金森病相关的震颤。枸橼酸奥芬那君具有良好的神经保护作用,可用于神经退行性疾病的研究[1][2]。 体外研究(In Vitro):Orphenadrine citrate (12 μM;24.5 h) 对 3-NPA 诱导的神经毒性小脑颗粒细胞显示出神经保护作用[1]。 MCE尚未独立确认这些方法的准确性。 仅供参考。 体内研究(In Vivo):Orphenadrine citrate (10、20、30 mg/kg;腹腔注射;每天一次,持续 3 天) 以剂量依赖性方式降低 3-NPA 诱导的死亡率[1]。Orphenadrine citrate (30 mg/kg;腹腔注射;每天一次,持续 3 天) 在体内显示出对抗 3-NPA 诱导的神经元损伤的活性[1]。 MCE尚未独立确认这些方法的准确性。 仅供参考。 分子量:461.50 Formula:C24H31NO8 性状:固体 颜色:White to off-white 中文名称:奥芬那君;邻甲苯海拉明 运输条件:美国大陆地区的室温;其他地区可能有所不同。 储存方式: 4°C,密封保存,避光防潮 *溶剂保存:-80°C,6个月;-20°C,1个月(密封保存,避光防潮) 提供质量检测报告:Data Sheet、SDS、COA、HNMR、LCMS、产品使用指南 产品活性:Orphenadrine citrate 是一种口服有效的非竞争性 NMDA 受体拮抗剂 (可透过血脑屏障),其 Ki 值为 6.0 μM。Orphenadrine citrate 能缓解因肌肉拉伤、扭伤或其他损伤引起的僵硬、疼痛和不适,也用于缓解帕金森病引起的颤抖。Orphenadrine citrate 具有较好的神经保护作用,可用于神经退行性疾病的研究。 相关产品:Rosiglitazone | Rosiglitazone (Standard) | Probenecid | Verapamil | Ko 143 | Verapamil (Standard) | Probenecid (Standard) | Fluphenazine dihydrochloride | L-Carnitine | Celecoxib | Metformin | Cyclosporin A 热门产品线:抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类 Trending products:Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides MCE 抑制剂: MedChemExpress 信号通路产品覆盖细胞凋亡、自噬、细胞周期与 DNA 损伤、表观遗传、GPCR/G 蛋白、免疫与炎症、JAK/STAT、MAPK/ERK、膜转运体与离子通道、代谢酶与蛋白酶、神经信号、NF-κB、PI3K/Akt/mTOR、PROTAC、蛋白酪氨酸激酶/受体酪氨酸激酶、干细胞/Wnt、TGF-β/Smad 及维生素 D/核受体等研究方向,为肿瘤、感染、炎症与免疫、神经系统疾病、代谢性疾病、心血管疾病和内分泌研究提供多维度的产品选择,助力客户发表文献超 80,000 篇。 相关产品可根据具体情况提供化学结构、作用靶点、生物活性、纯度、溶解度、体内外研究信息、参考文献及质量分析报告 (COA)等资料。 客户发表文献: 参考文献: 品牌介绍:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||